Clinical trial NCT01389193: Ibudilast in the Treatment of Patients With Chronic Migraine.
Official title: Targeting Glial Inhibition to Attenuate Chronic Migraine: AN INTERNATIONAL DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF IBUDILAST
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Migraine Headache
Keywords: ibudilast
migraine
glial cell
Lead sponsor: Aalborg University
Sponsor class: OTHER
Collaborators: name: The Ministry of Science, Technology and Innovation, Denmark
name: Migraine Research Foundation
First posted: 2011-07-08
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This will be a double-blind, randomised, placebo-controlled, two period cross over study of ibudilast in the treatment of chronic migraine.

For participants resident in Adelaide, South Australia (i.e. "local participants"):

The study will involve a screening visit followed by eight visits to the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH), for baseline testing, initiation of the study medications and ongoing data collection (one baseline and three study visits during each treatment period).

At the baseline visit, blood samples to assess biomarkers (glutamate, calcitonin gene-related peptide, glial fibrillary acidic protein and S100β) will be taken. Patients will then be randomised (in a 1:1 ratio) to commence either ibudilast or placebo treatment, which will continue for 8 weeks. Subsequently participants will undergo a 4-week washout period. At the end of the washout period a second 8-week treatment block with the alternative treatment will commence.

Patients will complete a headache diary daily for at least 4 weeks prior to the baseline visit, throughout the treatment and washout periods and for 4 weeks after treatment ceases. The diary will record headache frequency, duration, intensity, pain characteristics and medication intake for comparison with baseline data.

From screening until the final study visit (over a minimum of 6 months) a total of approximately 200 mL in blood samples will be taken from each local participant.

For participants located in country or interstate locations:

The same study will be undertaken, but instead of attending the Pain and Anaesthesia Research Clinic (PARC), within the Royal Adelaide Hospital (RAH) for screening and study visits, these will be managed remotely through:

basic input from the participant's GP during the screening period correspondence with the PI and study staff via registered post, phone or Skype scheduled visits to the nearest pathology collection centre for blood biochemistry and haematology analysis

Interstate or country participants will also be exempt from collection of blood samples for biomarker analysis, hence a total of approximately 120 mL of blood samples will be taken from each interstate or country participant.


Eligibility criteria: Inclusion Criteria:

Men and women aged between 18 to 65 years Migraine with or without aura, as diagnosed according to the second edition International Classification of Headache Disorders (ICHD-II) Onset of migraine before 50 years of age Headache on 15 or more days per month Migraine-like headache on 8 or more days per month, as per the IHS guidelines

Exclusion Criteria:

* Change in type or dose of migraine prophylactic medication in last 3 months
* Medication overuse headache as diagnosed according to the ICHD-IIR
* Post-traumatic headache as diagnosed according to the ICHD-II
* Other dominant chronic pain condition
* Known active inflammatory diseases such as rheumatoid arthritis
* History of recent cerebrovascular disorder
* Unable to provide written informed consent
* Unable to read and write in English
* Severe psychological/psychiatric disorders
* Recent history of significant trauma, as determined by the Principal Investigator including major surgery within the previous 2 months or major surgery planned during the treatment period
* Recent history of drug or alcohol abuse
* Any clinically significant findings on screening blood sample results
* Current malignancy
* Known hypersensitivity to ibudilast or excipients in Ketas® formulation
* Renal or hepatic impairment, defined as baseline GFR (as calculated by the Cockcroft-Gault equation) of \<60 mL/min, LFTs (excluding bilirubin) \> 3 times the upper limit of normal or bilirubin \> 2 times the upper limit of normal
* For females of childbearing potential:

  * Pregnancy
  * Lack of adequate contraception (abstinence, double barrier method, intrauterine device, surgical sterilization (self or partner), hormonal contraceptive methods (oral, injected, or implanted)
  * Breastfeeding

Primary outcomes:
measure: Primary efficacy end point
timeFrame: 8 weeks
Secondary outcomes:
measure: Secondary efficacy end points
timeFrame: 8 weeks
measure: Serum biomarker levels
timeFrame: 8 weeks
Other outcomes:
measure: safety and tolerability of ibudilast
timeFrame: 8 weeks
Locations:
city: Adelaide
country: Australia
facility: School of Medical sciences, University of Adelaide
Study officials:
affiliation: School of Medical sciences, University of Adelaide, Adelaide, Australia
name: Paul Rolan, MBBS FRACP FFPM MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Aalborg University
name: Parisa Gazerani, PharmD, PhD
role: PRINCIPAL_INVESTIGATOR
References: